
Oncology NEWS International
- Oncology NEWS International Vol 16 No 8
- Volume 16
- Issue 8
US consumers are shielded from the cost of healthcare
In the article "Trustee warns that Medicare is heading for insolvency" (Oncology NEWS International July 2007, page 26), Dr. Thomas Saving made some excellent recommendations for changing how Medicare is financed.
In the article "Trustee warns that Medicare is heading for insolvency" (Oncology NEWS International July 2007, page 26), Dr. Thomas Saving made some excellent recommendations for changing how Medicare is financed. There is, however, one recommendation that Dr. Saving alluded to, but did not emphasize, when he stated that "beneficiaries are shielded from the fiscal realities of the medical care they consume."
This situation is further exacerbated by the care delivered, especially end-of-life-care, at the patient's directive. Thus, often patients and their families want everything done because that is the only way the patient can stay in the hospital and avoid home care and costs. Often these patient directives also economically benefit the caregivers.
In the current healthcare system, there are lots of winners. The only losers are the next generation of Americans, who will be left with the tab.
Unless we use incentives and disincentives in healthcare by denying payment and/or enforcing Dr. Saving's advice that "the first dollars spent on healthcare are the responsibility of the consumer," the US healthcare delivery system is unlikely to see much improvement.
Gilbert A. Lawrence, MD, DMRT, FRCRRadiation Oncology, Faxton Hospital Cancer CenterUtica, New York
Articles in this issue
almost 19 years ago
Avoiding copay shockalmost 19 years ago
Induction chemo increases survival in unresectable NSCLCalmost 19 years ago
Superselective chemo strategies for HCCalmost 19 years ago
'Value meal dosing' of lapatinib is proposedalmost 19 years ago
AMA approves CPT code for Axxent electronic brachytherapyalmost 19 years ago
Zevalin/R after CHOP-R doubles CRs in follicular NHLalmost 19 years ago
RT plus local paclitaxel gel promising in esophageal caalmost 19 years ago
GeneSearch BLN Assay gets FDA approval for node assessment during surgeryalmost 19 years ago
TH vs TCH in metastatic breast cancer: 'Take your pick'Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Content


130 Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) Vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1–Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYNOTE-D19 Study
















































